NEW YORK / Feb 03, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer, will answer questions about the company at 1:00 p.m. ET.
Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$55.83 |
| Daily Change: | -0.98 -1.73 |
| Daily Volume: | 8,617,715 |
| Market Cap: | US$113.330B |
December 23, 2024 December 09, 2024 November 19, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
